ライフサイエンスコーパス: vaccine candidate

1 justify further clinical evaluation of this vaccine candidate.

2 highlighting the value of NS1 as a potential vaccine candidate.

3 powerful carrier, bacteriophage Qbeta, as a vaccine candidate.

4 (50)), demonstrating its potential as a safe vaccine candidate.

5 major protein subunit, PilA, is a promising vaccine candidate.

6 hors identify SPy_2191 as a cross-protective vaccine candidate.

7 -1 strain Ab4 (Ab4DeltaORF2) was tested as a vaccine candidate.

8 by adding to the safety profile of this live vaccine candidate.

9 ectodomain (M2e) is a universal influenza A vaccine candidate.

10 mune responses after 1 intramuscular dose of vaccine candidate.

11 target of acquired immunity and a potential vaccine candidate.

12 he effectiveness of the RV144 clinical trial vaccine candidate.

13 vivax Duffy binding protein (PvDBP), a lead vaccine candidate.

14 esents a promising novel live-attenuated RSV vaccine candidate.

15 the first study describing it as a potential vaccine candidate.

16 n on the development and application of this vaccine candidate.

17 ts reevaluation of NS1 as a universal dengue vaccine candidate.

18 -like fold and hence can act as an efficient vaccine candidate.

19 otective efficacy using a broadly protective vaccine candidate.

20 means for large-scale production of this HCV vaccine candidate.

21 e conjugative plasmid pIP501, as a potential vaccine candidate.

22 i-FH antibodies, justifying CspZ-YA as an LD vaccine candidate.

23 nd we believe it represents a promising ZIKV vaccine candidate.

24 ults support further evaluation of this mRNA vaccine candidate.

25 a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.

26 luation as a potential transmission-blocking vaccine candidate.

27 s the leading malaria pre-erythrocytic-stage vaccine candidate.

28 urther development of this potent SARS-CoV-2 vaccine candidate.

29 (RON2), all of which are blood-stage malaria vaccine candidates.

30 ordetella resulted in the development of new vaccine candidates.

31 ve the way for testing of potential drug and vaccine candidates.

32 in to evaluate the safety of live attenuated vaccine candidates.

33 ow variability which could render them ideal vaccine candidates.

34 ts and mutations observed in live-attenuated vaccine candidates.

35 and small molecules and the design of novel vaccine candidates.

36 re pathogenesis and immunity and to evaluate vaccine candidates.

37 amplifying clinical isolates and generating vaccine candidates.

38 roved potential as universal influenza virus vaccine candidates.

39 elate of protection for evaluation of plague vaccine candidates.

40 ight help to increase the efficacy of future vaccine candidates.

41 EHEC O157:H7 genome to select new potential vaccine candidates.

42 inclusion of glycoprotein B antigens in CMV vaccine candidates.

43 onization therefore offer great potential as vaccine candidates.

44 mbinant viruses have been generated as novel vaccine candidates.

45 immunity in the search for superior malaria vaccine candidates.

46 l nucleic acids (SNAs) functioning as cancer-vaccine candidates.

47 inely used to evaluate the safety of new RSV vaccine candidates.

48 he wild-type HA from viruses selected as the vaccine candidates.

49 -free virus, they are not induced by current vaccine candidates.

50 djuvant for immunoprophylactic schistosomula vaccine candidates.

51 istosomulum should be considered as possible vaccine candidates.

52 n is important in guiding the development of vaccine candidates.

53 can provide selection criteria to rank order vaccine candidates.

54 ce of Bp and Bm lipopolysaccharides (LPS) as vaccine candidates.

55 r evaluation and development of tuberculosis vaccine candidates.

56 stly to generate deoptimized viruses used as vaccine candidates.

57 ch as serosurveillance and the evaluation of vaccine candidates.

58 vate T-cells indicating that they are cancer vaccine candidates.

59 ass scale clinical translation of successful vaccine candidates.

60 e proteins and considered their potential as vaccine candidates.

61 ed for the development of stable, attenuated vaccine candidates.

62 e stools of 15 (100%) participants receiving vaccine candidate 1 and 13 (87%) participants receiving

63 didate 1 and 13 (87%) participants receiving vaccine candidate 2.

64 ays apart, of either placebo or the BNT162b2 vaccine candidate (30 mug per dose).

65 d GII.4c norovirus virus-like particle (VLP) vaccine candidate adjuvanted with alum and monophosphory

66 Additionally, vaccine candidates adjuvanted by a robust formulation of

67 e also examined the in vivo stability of the vaccine candidates after a single passage in African gre

68 pe domain III protein (DENVrEDIII), a potent vaccine candidate against DENV.

69 suggest that SPy_2191 can act as a universal vaccine candidate against GAS infections.

70 mmune responses and thus, can be a potential vaccine candidate against SARS-CoV-2.

71 nce assessment and the capability to predict vaccine candidates against a new emerging pathogen.

72 sP2 VLoop may be used for development of new vaccine candidates against alphavirus infections and vec

73 research, we developed novel live attenuated vaccine candidates against chikungunya virus by applying

74 salivary proteins demonstrated as potential vaccine candidates against cutaneous and visceral leishm

75 , selection and validation process for novel vaccine candidates against gram-negative bacteria, which

76 designing new, highly-specific, Bm86 antigen vaccine candidates against R. microplus circulating in M

77 rationale for and current status of various vaccine candidates against S. Paratyphi and nontyphoidal

78 sights towards the design of diagnostics and vaccine candidates against this high priority coronaviru

79 Vaccine candidates against ZIKV are coming online, but i

80 Trial groups were defined according to vaccine candidate, age of the participants, and vaccine

81 e 1 (HIV-1) genotypes are being developed as vaccine candidates aimed at the induction of broadly neu

82 With several vaccine candidates already being tested in clinical tria

83 ul vaccine will require improvement over the vaccine candidate (ALVAC) used in the RV144 study.

84 RTS,S is an advanced malaria vaccine candidate and confers significant protection aga

85 velopment of this promising nanoparticle RSV vaccine candidate and establish computationally designed

86 he emm gene, is a major virulence factor and vaccine candidate and forms the basis of a number of cla

87 rVSV-ZEBOV) is the most advanced Ebola virus vaccine candidate and is currently being used to combat

88 Mycobacterium tuberculosis, is an attractive vaccine candidate and marker of protective immunity agai

89 inant virus is a safe and effective bivalent vaccine candidate and that the expression of both F and

90 anting Y. pestis OMVs provide a novel plague vaccine candidate and that the rational design of OMVs c

91 ht explain the lack of effectiveness of this vaccine candidate and/or design.

92 tly underway to evaluate the efficacy of two vaccine candidates and a broadly neutralizing antibody (

93 tically attenuated parasites both as malaria vaccine candidates and also as valuable tools to interro

94 While surface proteins are suitable vaccine candidates and can elicit antibacterial antibody

95 S-protein derivatives are components of vaccine candidates and diagnostic assays, as well as too

96 n of interest, have been used to down-select vaccine candidates and have provided efficacy data in su

97 dy levels will facilitate the advancement of vaccine candidates and maternal immunization.

98 tein 1 (Hcp1) and O-polysaccharide (OPS) are vaccine candidates and potential diagnostic antigens.

99 valuation for early up- or down-selection of vaccine candidates and potentially useful in support of

100 evant information for preclinical testing of vaccine candidates and therapeutic agents for COVID-19.

101 computational strategy to identify bacterial vaccine candidates and validate their immunogenicity usi

102 y chose an envelope containing the name of a vaccine candidate, and this determined their allocation;

103 pment of new drugs and therapeutic regimens, vaccine candidates, and diagnostics for the prevention a

104 activity for development of live attenuated vaccine candidates, and ISG15 as a novel biotherapeutic

105 II trials are already available for several vaccine candidates, and many have moved into phase III t

106 asion ligand that is a potential blood-stage vaccine candidate antigen; however, a naturally occurrin

107 Several Ebola vaccine candidates are available, but conducting randomi

108 and compare it to the sequence on which most vaccine candidates are based.

109 Various novel influenza vaccine candidates are being evaluated in animal studies

110 However, approaches to identify novel vaccine candidates are commonly laborious and protracted

111 Several plague vaccine candidates are currently at various stages of de

112 Several vaccine candidates are currently in preclinical and clin

113 Multiple vaccine candidates are under development, but no vaccine

114 Several cytomegalovirus (CMV) vaccine candidates are under development.

115 clinical and clinical evaluation of COVID-19 vaccine candidates as well as for vaccine design and opt

116 e reagents for accessing the antigenicity of vaccine candidates, as well as developing antibody-based

117 ), or 1 x 10(6) CFU of B. abortus S19 or the vaccine candidate B. abortus S19DeltavjbR and monitored

118 hortcomings of broadly reactive or universal vaccine candidates based on the hemagglutinin globular h

119 rim safety and immunogenicity data about the vaccine candidate BNT162b1 in younger adults have been r

120 particle-formulated, nucleoside-modified RNA vaccine candidates: BNT162b1, which encodes a secreted t

121 Serotype 35B is thus a likely future vaccine candidate, but due to their previous rarity, ser

122 The hemoglobin receptor (HgbA) is a leading vaccine candidate, but its efficacy in animal models is

123 RTS,S is the leading malaria vaccine candidate, but only confers partial efficacy aga

124 tional importance, DBP is considered a prime vaccine candidate, but variation in B-cell epitopes at t

125 We evaluated RSV M-null as a potential vaccine candidate by determining its pathogenicity, immu

126 experience with developing and testing viral vaccine candidates can inform expectations regarding the

127 ticipants each received a single dose of one vaccine candidate (candidate 1, S2/cre5/S15domV/rec1/hif

128 V-seropositive) women, we hypothesize that a vaccine candidate capable of eliciting immune responses

129 erage, 29 yr) were vaccinated with the Ebola vaccine candidate chimpanzee adenovirus type 3-vectored

130 We have previously described a vaccine candidate composed of single-cycle LASV replicon

131 on.IMPORTANCE Most current and new influenza vaccine candidates consist of a single influenza virus p

132 This study demonstrates that a VLP vaccine candidate containing a stabilized prefusion F pr

133 sponse induced by our epicutaneous Pertussis vaccine candidate containing non-adsorbed recombinant Pe

134 demonstrate that live-attenuated Zika virus vaccine candidates containing deletions in the 3' untran

135 on, with novel RSV virus-like particle (VLP) vaccine candidates containing stabilized prefusion RSV F

136 trolled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and pote

137 ion cycle between mosquitoes and naive mice, vaccine candidates could be transmitted by mosquito bite

138 To determine vaccine candidate coverage, we investigated all of the p

139 the guinea pig model confirm efficacy of the vaccine candidate, demonstrate that single-cycle replica

140 From the numerous vaccine candidates designed and tested as part of our V2

141 o evaluate suboptimal dosing for any new RSV vaccine candidate developed for seronegative infants.

142 hod was then successfully applied to several vaccine candidate developmental projects, such as the he

143 tested in the insect and mammalian host, the vaccine candidates did not cause disease, elicited stron

144 mmunization with a replication-defective HSV vaccine candidate, dl5-29, leads to transfer of virus-sp

145 n this model, vaccination with the prototype vaccine candidate dscCfaE is protective against CF-homol

146 ated to DT protein to provide glycoconjugate vaccine candidates (DT-Hexa, DT-Hepta, and DT-Octa) that

147 ein was previously identified as a potential vaccine candidate due to its conservation and stable exp

148 This Ebola vaccine candidate elicited anti-Ebola antibody responses

149 Moreover, we found that the vaccine candidates elicited protective immunity related

150 In both younger and older adults, the two vaccine candidates elicited similar dose-dependent SARS-

151 Emergency of International Concern, multiple vaccine candidates entered clinical trials, now totaling

152 ind, dose-escalation trials of an rVSV-based vaccine candidate expressing the glycoprotein of a Zaire

153 el replicating poxvirus NYVAC-based HIV/AIDS vaccine candidates expressing clade C HIV-1 antigens, wi

154 In this study, we developed a series of DNA vaccine candidates expressing different forms of the SAR

155 Here, we generated measles virus (MeV)-based vaccine candidates expressing the SARS-CoV-2 spike glyco

156 Many vaccine candidates focus on the Spike protein, as it is

157 B-linked FP8-rTTHC appears to be a promising vaccine candidate for advancing to clinical assessment.

158 (NS) 1 has been considered to be a desirable vaccine candidate for its ability to induce Ab and compl

159 Therefore, testing this vaccine candidate for its protective capacity is warrant

160 vasion of red blood cells and is a potential vaccine candidate for malaria.

161 ngs demonstrate that FILORAB3 is a promising vaccine candidate for Marburg virus disease.IMPORTANCE M

162 e protective immune response and a promising vaccine candidate for P. vivax malaria.

163 iosis, in mice and would be a promising oral vaccine candidate for protection against plague and yers

164 and therefore represents a new and promising vaccine candidate for the global fight against ZIKV.

165 By far the most immunogenic vaccine candidates for antibody responses are recombinan

166 enicity make the designed mutants attractive vaccine candidates for EEEV infection.

167 s an approach for generating live-attenuated vaccine candidates for emerging coronaviruses.

168 s has been made toward identifying potential vaccine candidates for highly pathogenic human CoVs, inc

169 n for the rational design of live attenuated vaccine candidates for other viral hemorrhagic fevers.

170 easing sophistication have been evaluated as vaccine candidates for over 30 years.

171 arget for rational design of live attenuated vaccine candidates for RSV and perhaps other pneumovirus

172 , these recombinant viruses may be promising vaccine candidates for RSV.

173 ighly attenuated, and immunogenic live virus vaccine candidates for RSV.IMPORTANCE Despite tremendous

174 lycan analysis of one of the leading subunit vaccine candidates from Novavax, which is based on a ful

175 Many promising vaccine candidates from pathogenic viruses, bacteria, an

176 Our results using inactivated vaccine candidates from the human pandemic preparedness

177 ur findings demonstrate that the ID93/GLA-SE vaccine candidate given as a BCG-prime boost regimen con

178 ustrated herein was focused on the influenza vaccine candidate H1ssF, a hemagglutinin (group 1) stabi

179 Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical mo

180 Although many vaccine candidates have been generated, few have demonst

181 Many vaccine candidates have been tested using various strate

182 the subunit approach; however, many subunit vaccine candidates have had limited efficacy in settings

183 esses and failures in developing and testing vaccine candidates have provided a roadmap for future va

184 Several Zika virus (ZIKV) vaccine candidates have recently been described which us

185 Several HIV-1 and SIV vaccine candidates have shown partial protection against

186 ion and suboptimal immunogenicity of malaria vaccine candidates have slowed the development of a Plas

187 ata indicated that PIV5/F is a promising RSV vaccine candidate.IMPORTANCE A safe and efficacious resp

188 izes further evaluation of Ab4DeltaORF2 as a vaccine candidate.IMPORTANCE Nasal equine herpesvirus ty

189 data suggest that KDKE(4A)-SYA may be a PEDV vaccine candidate.IMPORTANCE PEDV is the most economical

190 tly reduced, rendering the viruses promising vaccine candidates.IMPORTANCE Chikungunya fever is a deb

191 eveloping antivirals and/or attenuated viral vaccine candidates.IMPORTANCE Several arenaviruses, such

192 tional design strategies for new Ebola virus vaccine candidates.IMPORTANCE The pathogenesis of Ebola

193 bivalent norovirus virus-like particle (VLP) vaccine candidate in 50 healthy 18- to 49-year-olds.

194 tegy for improved production of C. difficile vaccine candidate in E. coli by using restricted DO grow

195 the potential role of a live-attenuated MAYV vaccine candidate in host's protection from disease indu

196 data supported the further assessment of the vaccine candidates in children and infants.

197 The leading dengue virus vaccine candidates in clinical testing are all based on

198 The current leading Zika vaccine candidates in clinical testing are based on live

199 With few Schistosoma vaccine candidates in clinical trials, unexplored antige

200 l preclinical studies evaluate new influenza vaccine candidates in immunologically naive animals.

201 rmore, C-prM-E and prM-E VLPs were tested as vaccine candidates in mice and compared to DNA vaccinati

202 led to increases in immunogenicity of HIV-1 vaccine candidates in nonhuman primates.

203 conducted two trials to assess potential WNS vaccine candidates in wild-caught Myotis lucifugus.

204 ity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to

205 38G mutant has several features for an ideal vaccine candidate, including significantly reduced neuro

206 Vaccine candidates induce both a neutralizing antibody r

207 The mRNA-1273 vaccine candidate induced antibody levels exceeding thos

208 BACKGROUNDThe live attenuated BPZE1 vaccine candidate induces protection against B. pertussi

209 ructure and immunobiology is advancing novel vaccine candidates into human trials.

210 .IMPORTANCE The duration of immunity for any vaccine candidate is crucial.

211 referred conformation, and a current leading vaccine candidate is the BG505 DS-SOSIP variant, compris

212 In fact, the first vaccine candidate launched into clinical trials is an mR

213 ke protein, which is the basis for different vaccine candidates, matches optimized vaccine inserts, b

214 and advanced in clinical testing, additional vaccine candidates may be needed to provide protection a

215 Efforts to develop second-generation vaccine candidates may concentrate on adjuvants that mod

216 in humans and tested a live-attenuated MAYV vaccine candidate (MAYV/IRES).

217 ed to directly measure the titers of various vaccine candidate molecules in cell culture without a pr

218 ccinated with a measles-vectored chikungunya vaccine candidate, MV-CHIK, were analyzed.

219 To control TMUV infection, a live-attenuated vaccine candidate of TMUV was developed in our previous

220 ansduced mice enabled rapid assessments of a vaccine candidate, of human convalescent plasma, and of

221 V strains such as low-replicating attenuated vaccine candidates or low-cell culture passage clinical

222 hAd63-MVA PfUIS3 was coadministered with the vaccine candidate P. falciparum thrombospondin-related a

223 The vaccine candidate PAMVAC is based on a recombinant fragm

224 validation for the potential utility of this vaccine candidate particularly in East-Asian countries,

225 Plasmodium falciparum transmission-blocking vaccine candidate Pfs25 has largely been conducted in pr

226 A vaccine candidate, PorB induces antibody responses that

227 Interestingly, the potential tetravalent VLP vaccine candidate provided strong neutralizing antibody

228 mental in determining which of the many ZIKV vaccine candidates provides the highest degree of protec

229 The comparative testing of a large number of vaccine candidates requires a quantitative and reproduci

230 nic rPfMSP8 as a carrier protein for leading vaccine candidates rPfMSP1(19) and rPfs25 facilitated an

231 Malaria vaccine candidate RTS,S/AS01 is based on the central and

232 These findings suggest that a single vaccine candidate should be efficacious against currentl

233 ic fever pathogenesis and suggest that a GAS vaccine candidate should offer broad coverage against a

234 rculate in West Africa, and therefore, ideal vaccine candidates should elicit immunity to all lineage

235 These vaccine candidates should have a low risk of deattenuati

236 By replacing conventional phase 3 testing of vaccine candidates, such trials may subtract many months

237 This provides an improved vectored RSV vaccine candidate suitable for pediatric clinical evalua

238 identifies INO-4800 as a potential COVID-19 vaccine candidate, supporting further translational stud

239 mmunogenicity of Takeda's tetravalent dengue vaccine candidate (TAK-003) in healthy children and adul

240 e 3 randomized trial of a tetravalent dengue vaccine candidate (TAK-003) in regions of Asia and Latin

241 Takeda's live-attenuated tetravalent dengue vaccine candidate (TAK-003).

242 experience to generate a synthetic DNA-based vaccine candidate targeting SARS-CoV-2 S protein.

243 Several vaccine candidates targeting defined surface antigens of

244 A leading vaccine candidate targets 30 of the > 200 emm types of G

245 of sensitive diagnostic tools and potential vaccine candidate targets.

246 We summarize the immunogenicity of leading vaccine candidates tested to date in animals and humans

247 and rhesus macaque models to accelerate HIV vaccine candidate testing in human trials.

248 ccine generated in this study is a promising vaccine candidate that can be further developed to battl

249 combined these mutations to engineer a novel vaccine candidate that induced additive amounts of inter

250 rime-boost regimen for administration of the vaccine candidate that is similar to the one used in the

251 dentified an effective ST2 neoglycoconjugate vaccine candidate that was identified using a medicinal

252 ory role for advancing the range of Shigella vaccine candidates that are currently in development.

253 Additionally, other vaccine candidates that are currently undergoing clinica

254 vel monovalent oral type-2 poliovirus (OPV2) vaccine candidates that are genetically more stable than

255 al of the neonatal calf model to evaluate TB vaccine candidates that are to be administered via the r

256 how to improve the cHA antigens to generate vaccine candidates that both induce a broad antistalk re

257 ction of a minimal number of M peptide-based vaccine candidates that elicit broadly protective immuni

258 rtant need for prophylactic anti-Ebola virus vaccine candidates that elicit long-lasting immune respo

259 avenue for the development of preventive HCV vaccine candidates that induce bNAbs at higher yield and

260 pact design of new universal T-cell-inducing vaccine candidates that minimise detrimental effects of

261 may be useful for generating live attenuated vaccine candidates that prevent disease and fecal spread

262 odel of recurrent genital herpes, of subunit vaccine candidates that were based on eight recombinantl

263 odel of recurrent genital herpes, of subunit vaccine candidates that were based on eight recombinantl

264 In the case of African swine fever virus vaccine candidates, this issue has received little atten

265 n strain, makes the 5-combo-OMVs a promising vaccine candidate to be tested in clinics.

266 ough human trials is crucial for advancing a vaccine candidate to clinics.

267 o this end, we used a trivalent glycoprotein vaccine candidate to demonstrate that offspring are prot

268 vaccine, supporting the progression of this vaccine candidate to ongoing phase 2/3 trials to assess

269 zid-based regimens, and there is a promising vaccine candidate to prevent the progression of infectio

270 ed to define the efficacy of the multivalent vaccine candidate to protect against lethal virus challe

271 s progressed from being an attractive cancer vaccine candidate to recognition as a key player in regu

272 Virus Like Particle (VLP) based multivalent vaccine candidate to target these diseases by using stab

273 ress three different AMA1-DiCo-based malaria vaccine candidates to develop a vaccine cocktail.

274 emagglutinin-based universal influenza virus vaccine candidates to induce broadly cross-reactive anti

275 Testing of vaccine candidates to prevent infection with severe acut

276 an improved model to evaluate the ability of vaccine candidates to protect against a serious manifest

277 Several vaccine candidates to protect against severe acute respi

278 nventionally used to evaluate the ability of vaccine candidates to safely elicit antibodies that bind

279 we determined the efficacy of ZIKV NS1-based vaccine candidates using two delivery platforms, methylt

280 -G-DeltaI177L is one of the few experimental vaccine candidate virus strains reported to be able to i

281 GMMA expressing this vaccine candidate was immunogenic, raising a specific an

282 C virus [HCV] genotype 1a) gpE1/gpE2 (E1E2) vaccine candidate was previously shown by our group to p

283 This live vaccine candidate was temperature-sensitive, genetically

284 To improve our previous vaccine candidate, we developed four new candidates that

285 To identify novel blood-stage malaria vaccine candidates, we constructed a library of 1,827P.

286 is an effective approach for assessing ETEC vaccine candidates, we used it to evaluate the ability o

287 The vaccine candidates were evaluated in a rodent hookworm c

288 the PIV5-RSV-F (HN-L) candidate, additional vaccine candidates were generated in which the gene for

289 Several potential vaccine candidates were identified and tested for their

290 The adjuvant-free vaccine candidates were orally administered to mice and

291 PfSPZ-CVac is a highly efficacious vaccine candidate; when we are able to optimize the immu

292 this study, we compared a single-cycle viral vaccine candidate, which is unique in that it elicits pr

293 ion. Therefore, unlike the leading EBV gp350 vaccine candidate, which only protects B cells from infe

294 this virus, and the development of suitable vaccine candidates will be aided by an improved understa

295 se selected pathways to synthesize a protein vaccine candidate with an alpha-galactose adjuvant motif

296 lope protein domain III (EDIII) is a subunit vaccine candidate with cross-neutralization activity; ho

297 nerated in this study is a promising subunit vaccine candidate with high efficacy in preventing ZIKV

298 impregnated bed nets, we developed a malaria vaccine candidate with the aim of reducing sequestration

299 YopB/LcrV+dmLT is a promising subunit vaccine candidate with the potential to elicit broad pro

300 n assays in order to evaluate potential SAT2 vaccine candidates with improved stability.